AR123385A1 - Inhibidores de la secreción de proteínas - Google Patents
Inhibidores de la secreción de proteínasInfo
- Publication number
- AR123385A1 AR123385A1 ARP210102441A ARP210102441A AR123385A1 AR 123385 A1 AR123385 A1 AR 123385A1 AR P210102441 A ARP210102441 A AR P210102441A AR P210102441 A ARP210102441 A AR P210102441A AR 123385 A1 AR123385 A1 AR 123385A1
- Authority
- AR
- Argentina
- Prior art keywords
- 3alkylene
- 6alkyl
- het
- halo
- 6alkylene
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000028327 secretion Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 125000005843 halogen group Chemical group 0.000 abstract 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 9
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000005842 heteroatom Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 abstract 2
- -1 C(O)N(RN)2 Chemical group 0.000 abstract 2
- 244000137850 Marrubium vulgare Species 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 241000209149 Zea Species 0.000 abstract 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 2
- 235000005822 corn Nutrition 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000006574 non-aromatic ring group Chemical group 0.000 abstract 2
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 abstract 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 abstract 1
- FYDYYNBALSEMHM-UHFFFAOYSA-N 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine Chemical compound C1CCCN2C=NC=C21 FYDYYNBALSEMHM-UHFFFAOYSA-N 0.000 abstract 1
- ZWETXQBHVRWLPW-UHFFFAOYSA-N 6,7-dihydro-5h-pyrrolo[1,2-a]imidazole Chemical compound C1=CN2CCCC2=N1 ZWETXQBHVRWLPW-UHFFFAOYSA-N 0.000 abstract 1
- 101100476756 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) sec-61 gene Proteins 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 abstract 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 abstract 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
En la presente se proporcionan inhibidores de secreción, tales como inhibidores de Sec61, métodos para su preparación, composiciones farmacéuticas relacionadas y métodos para usarlos. Reivindicación 1: Un compuesto, o una sal aceptable desde el punto de vista farmacéutico de este, que tiene una estructura de la fórmula [1] ó [1] en donde R¹ es H, C₁₋₃alquilo, o SO₂C₁₋₆alquilo; cada uno de X e Y es independientemente N o CRC; el anillo A es un heteroarilo de 6 miembros con 2 átomos de nitrógeno en el anillo; RA es H, C₁₋₆alquilo, ORN, N(RN)₂, OC₁₋₆alquileno-N(RN)₂, o OC₁₋₆alquileno-ORN; RB es C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₃alquileno-C₁₋₃alcoxi, O-C₁₋₃alquileno-C₁₋₃alcoxi, C₁₋₆haloalquilo, C₁₋₆hidroxialquilo, O-C₁₋₆hidroxialquilo, halo, C₀₋₃alquileno-CO₂RN, C₀₋₃alquileno-N(RN)₂, OC₁₋₃alquileno-N(RN)₂, NO₂, C₀₋₃alquileno-C(O)N(RN)₂, C₀₋₃alquileno-N(RN)C(O)RN, OC₁₋₃alquileno-N(RN)C(O)RN, C₀₋₃alquileno-N(RN)C(O)N(RN)₂, C₀₋₃alquileno-N(RN)SO₂RN, C₀₋₃alquileno-N(RN)C(O)ORN, C₀₋₃alquileno-OC(O)N(RN)₂, C₀₋₃alquileno-Het, C₀₋₃alquileno-OHet, C₀₋₃alquileno-NHCO₂Het, C₀₋₃alquileno-OC(O)Het, C₀₋₃alquileno-N(RN)Het o C₀₋₃alquileno-N(RN)C(O)Het, o si (1) m es 1 ó 2; (2) al menos uno de X e Y, (3) al menos un RC es distinto de H, o (4) al menos uno de o y p es 1, entonces RB puede ser H; o si Y es CRC, entonces RC y RB pueden combinarse para formar un anillo fusionado de 6 miembros con los carbonos a los que están unidos que tienen 0 - 2 heteroátomos de anillo seleccionados de N, O y S y opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados independientemente de oxo, halo y C₁₋₆alquilo; Het es un anillo aromático o no aromático de 4 - 7 miembros con 0 - 3 heteroátomos en el anillo seleccionados de N, O y S, y Het está opcionalmente sustituido con 1 ó 2 sustituyentes seleccionados independientemente de C₁₋₆alquilo, halo, ORN, oxo, C(O)RN, C(O)C₃₋₆cicloalquilo, C(O)N(RN)₂, SORN, SO₂RN, y SO₂N(RN)₂; cada RC es independientemente H, halo, C₁₋₆alcoxi, N(RN)₂, CN, Het, o C₁₋₆alquilo; n es 0, 1, ó 2; cada RD, cuando está presente, es independientemente halo, C₁₋₆alcoxi, o C₁₋₆alquilo; m es 0, 1, ó 2; cada Rˣ, cuando está presente, es independientemente halo o C₁₋₆alquilo; p es 0 ó 1; Rʸ, cuando está presente, es C₁₋₆alquilo o halo; o es 0 ó 1; Rᶻ, cuando está presente, es CN, halo, C(O)N(RN)₂, C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₆hidroxialquilo, o C₁₋₆haloalquilo; y cada RN es independientemente H, C₁₋₆alquilo, C₁₋₆hidroxialquilo, o C₁₋₆haloalquilo, con la condición de que cuando cada uno de m, p y o es 0, R¹ es H, X e Y son cada uno CRC, y al menos un RC es F, entonces RB no es F. Reivindicación 65: Un compuesto o la sales aceptables desde el punto de vista farmacéutico de este, que tienen una estructura de fórmula [2] en donde R¹ es H, C₁₋₃alquilo, o SO₂C₁₋₆alquilo; Het es oxazol, imidazol, pirazol, isoxazol, morfolina, tetrahidroquinolina, oxazolidinona, piperidinona, dihidrooxazol, pirazina, pirimidina, imidazo[1,2-a]piridina, 5,6,7,8-tetrahidroimidazo[1,5-a]piridina, piridin-2(1H)-ona, 6,7-dihidro-5H-pirrolo[1,2-a]imidazol, o quinolina, o cuando al menos uno de n y m es 1 ó 2, Het puede ser piridina, y cuando n es 1 ó 2, Het puede ser diazinilo; n es 0, 1, ó 2; cada RE, cuando está presente, es independientemente halo, C₁₋₆alquilo,C₀₋₆alquilen-C(O)N(RN)₂, C₀₋₆alquilen-N(RN)C(O)RN, C₀₋₆alquilen-CN, C₀₋₆alquilen-ORN, C₀₋₆alquilen-N(RN)₂, C₁₋₆haloalquilo, C₁₋₆haloalcoxi, C₁₋₆hidroxialquilo, C₀₋₆alquilen-CO₂RN, o C₀₋₆alquilen-[C(O)]₀₋₁- anillo aromático o no aromático de 3 - 6 miembros que tiene 0 - 2 heteroátomos del anillo independientemente seleccionados de N, O y S; en donde cuando RE comprende un anillo de 3 - 6, se sustituye opcionalmente con 1 - 2 grupos independientemente seleccionados de halo, C₁₋₆alquilo, CN, C₁₋₆haloalquilo, CO₂RN, C(O)RN, CON(RN)₂, N(RN)CORN, y ORN; m es 0, 1, ó 2; cada Rˣ, cuando está presente, es independientemente halo o C₁₋₆alquilo; o es 0 ó 1; Rᶻ, cuando está presente, es CN, halo, C(O)N(RN)₂, C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₆hidroxialquilo, o C₁₋₆haloalquilo; y cada RN es independientemente H, C₁₋₆alquilo, C₁₋₆hidroxialquilo, o C₁₋₆haloalquilo. Reivindicación 98: Un compuesto, o la sales aceptables desde el punto de vista farmacéutico de este, que tienen una estructura de la fórmula [3] en donde R¹ es H, C₁₋₃alquilo, o SO₂C₁₋₆alquilo; RA es H, C₁₋₆alquilo, ORN, N(RN)₂, OC₁₋₆alquilen-N(RN)₂, o OC₁₋₆alquilen-ORN; n es 0, 1, ó 2; el anillo A es fenilo o un heteroarilo de 6 miembros que tiene 1 ó 2 átomos del anillo de nitrógeno; cada RB, cuando está presente, es independientemente C₁₋₆alquilo, C₁₋₆alcoxi, C₁₋₆haloalcoxi, C₁₋₃alquilen-C₁₋₃alcoxi, C₁₋₆haloalquilo, C₁₋₆hidroxialquilo, halo, C₀₋₃alquilen-CO₂RN, C₀₋₃alquilen-C(O)N(RN)₂, C₀₋₃alquilen-N(RN)₂, OC₁₋₃alquilen-N(RN)₂, NO₂, C₀₋₃alquilen-N(RN)C(O)RN, C₀₋₃alquilen-N(RN)C(O)ORN, OC₁₋₃alquilen-N(RN)C(O)RN, C₀₋₃alquilen-N(RN)C(O)N(RN)₂, C₀₋₃alquilen-N(RN)SO₂RN, C₀₋₃alquilen-OC(O)N(RN)₂, C₀₋₃alquilen-Het, C₀₋₃alquilen-OHet, C₀₋₃alquilen-NHCO₂Het, C₀₋₃alquilen-OC(O)Het, C₀₋₃alquilen-N(RN)Het o C₀₋₃alquilen-N(RN)C(O)Het; Het es un anillo aromático o no aromático de 4 - 7 miembros que tiene 0 - 3 heteroátomos del anillo seleccionados de N, O, y S; Het está opcionalmente sustituido con 1 sustituyente seleccionado de C₁₋₆alquilo, ORN, halo, oxo, C(O)RN, C(O)N(RN)₂, SORN, SO₂N(RN)₂, y SO₂RN; R³ es C₁₋₆alquilen-X, C₂₋₆alquenilen-X, C₀₋₂alquilen-C₃₋₆carbociclo-C₀₋₂alquilen-X, o Ar, y el alquileno está opcionalmente sustituido con ORN; X es H, OC₁₋₃alquilo, C& Reivindicación 147: Un compuesto, o la sal aceptables desde el punto de vista farmacéutico de este, que tienen una estructura de fórmula [4], R¹ es H, C₁₋₃alquilo, o SO₂C₁₋₆alquilo; Het es heterociclo aromático o no aromático de 3 - 10 miembros que tiene 1 - 4 heteroátomos del anillo seleccionados de N, O, y S; n es 0, 1, ó 2; y cada RE, cuando está presente, es independientemente halo, C₁₋₆alquilo, fenilo, C(O)N(RN)₂, CN, C₀₋₆alquilen-ORN, C₀₋₆alquilen-N(RN)₂, C₁₋₆haloalquilo, C₁₋₆haloalcoxi, C₃₋₆cicloalquilo, o CO₂RN; en donde cuando RE es fenilo, se sustituye opcionalmente con 1 - 2 grupos independientemente seleccionados de halo, C₁₋₆alquilo, CN, C₁₋₆haloalquilo, C₁₋₆haloalcoxi, CO₂RN, CON(RN)₂, N(RN)CORN, y ORN; R³ es C₁₋₆alquilen-X, C₂₋₆alquenileno-X, Ar, o C₀₋₂alquilen-C₃₋₆carbociclo-C₀₋₂alquilen-X; X es H, OC₁₋₃alquilo, C&
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063072690P | 2020-08-31 | 2020-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123385A1 true AR123385A1 (es) | 2022-11-23 |
Family
ID=78087485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102441A AR123385A1 (es) | 2020-08-31 | 2021-08-31 | Inhibidores de la secreción de proteínas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230286973A1 (es) |
| EP (1) | EP4204417A1 (es) |
| JP (1) | JP2023539553A (es) |
| KR (1) | KR20230058655A (es) |
| CN (1) | CN116194455A (es) |
| AR (1) | AR123385A1 (es) |
| AU (1) | AU2021334388A1 (es) |
| BR (1) | BR112023003265A2 (es) |
| CA (1) | CA3190441A1 (es) |
| CL (1) | CL2023000582A1 (es) |
| CO (1) | CO2023002202A2 (es) |
| IL (1) | IL300736A (es) |
| MX (1) | MX2023002288A (es) |
| PE (1) | PE20231436A1 (es) |
| TW (1) | TW202227428A (es) |
| WO (1) | WO2022047347A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR128634A1 (es) * | 2022-02-28 | 2024-05-29 | Kezar Life Sciences | Inhibidores de sec61 y uso de los mismos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
| MX2021010314A (es) * | 2019-02-28 | 2021-11-12 | Kezar Life Sciences | Derivados de tiazol como inhibidores de la secreción de proteínas. |
-
2021
- 2021-08-30 IL IL300736A patent/IL300736A/en unknown
- 2021-08-31 CA CA3190441A patent/CA3190441A1/en active Pending
- 2021-08-31 EP EP21790626.2A patent/EP4204417A1/en active Pending
- 2021-08-31 WO PCT/US2021/048317 patent/WO2022047347A1/en active Application Filing
- 2021-08-31 AU AU2021334388A patent/AU2021334388A1/en active Pending
- 2021-08-31 AR ARP210102441A patent/AR123385A1/es unknown
- 2021-08-31 US US18/019,885 patent/US20230286973A1/en active Pending
- 2021-08-31 BR BR112023003265A patent/BR112023003265A2/pt unknown
- 2021-08-31 PE PE2023000533A patent/PE20231436A1/es unknown
- 2021-08-31 TW TW110132273A patent/TW202227428A/zh unknown
- 2021-08-31 CN CN202180052580.7A patent/CN116194455A/zh active Pending
- 2021-08-31 JP JP2023507944A patent/JP2023539553A/ja active Pending
- 2021-08-31 MX MX2023002288A patent/MX2023002288A/es unknown
- 2021-08-31 KR KR1020237009724A patent/KR20230058655A/ko unknown
-
2023
- 2023-02-27 CO CONC2023/0002202A patent/CO2023002202A2/es unknown
- 2023-02-28 CL CL2023000582A patent/CL2023000582A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116194455A (zh) | 2023-05-30 |
| JP2023539553A (ja) | 2023-09-15 |
| TW202227428A (zh) | 2022-07-16 |
| EP4204417A1 (en) | 2023-07-05 |
| US20230286973A1 (en) | 2023-09-14 |
| PE20231436A1 (es) | 2023-09-14 |
| CA3190441A1 (en) | 2022-03-03 |
| KR20230058655A (ko) | 2023-05-03 |
| BR112023003265A2 (pt) | 2023-05-02 |
| CO2023002202A2 (es) | 2023-03-27 |
| IL300736A (en) | 2023-04-01 |
| WO2022047347A1 (en) | 2022-03-03 |
| CL2023000582A1 (es) | 2023-09-29 |
| MX2023002288A (es) | 2023-03-10 |
| AU2021334388A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2018000295A1 (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| US10087195B2 (en) | Certain protein kinase inhibitors | |
| RU2018138471A (ru) | Гетероциклические соединения в качестве ингибиторов киназы RET | |
| KR101445458B1 (ko) | １Ｈ-이미다조［４,５-ｃ］퀴놀리논 유도체 | |
| JP2009507032A (ja) | 新規なイミダゾ系複素環 | |
| ES2416059T3 (es) | Tiazoles condensados antibacterianos | |
| KR20180041135A (ko) | Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물 | |
| HRP20151398T1 (hr) | Tricikliäśni derivati amina kao inhibitori protein tirozin kinaze | |
| AR080754A1 (es) | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 | |
| HRP20160744T2 (hr) | Heterocikličke tvari i njihova uporaba kao modulatora receptora tirozin kinaza tipa iii | |
| AR114443A1 (es) | Oxadiazoles fungicidas y un proceso para su preparación | |
| HRP20151232T1 (hr) | Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora | |
| AU2011217561B2 (en) | Hetarylaminonaphthyridines | |
| EA016028B1 (ru) | Конденсированные гетероциклические производные и их применение | |
| AU2013324396A1 (en) | Fused heterocyclic compounds as selective BMP inhibitors | |
| AR123385A1 (es) | Inhibidores de la secreción de proteínas | |
| JP2010505855A (ja) | 新規なイミダゾチアゾール類およびイミダゾオキサゾール類 | |
| AU2014231009A1 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| RU2002103379A (ru) | Антибактериальные гетеробициклические замещенные фенилоксазолидиноны | |
| BR122012012032A2 (pt) | Usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas | |
| NZ590784A (en) | Pyrazolopyridine kinase inhibitors | |
| PE20210658A1 (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| JP2012525367A5 (es) | ||
| CA2559128A1 (en) | Kinase inhibitors | |
| AR073262A1 (es) | Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1. |